Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees

Realty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year income plan.

Published September 16, 2026, 11:36am ET · 3 min read

A close-up, low-angle shot of a white rectangular corporate sign for Johnson & Johnson. The company's name is written in a distinctive red script, with 'MEDICAL DEVICES COMPANIES' in a smaller, gray sans-serif font below. Sunlight creates a bright lens flare on the left side of the sign, with blurred green tree foliage and a clear blue sky in the background. A white light pole is visible on the right, and parts of a modern building with blue-tinted windows can be seen in the distance.
The distinctive Johnson & Johnson sign stands as a symbol of the company's long-standing presence and consistent financial performance, underpinning its impressive dividend growth record. © Mario Tama / Getty Images News via Getty Images

For a retirement-focused investor deciding between Realty Income (NYSE:O | O Price Prediction) and Johnson & Johnson (NYSE:JNJ) right now, the question comes down to this: do you need the fattest possible monthly check, or do you want the safest compounding income stream money can buy? Both are legitimate income holdings. Only one wins on the metrics that actually matter over a 20-year retirement.

Let me break this down across three dimensions that a retiree should actually care about: current yield and cash cadence, dividend durability, and total-return trajectory.

Round 1: Yield and Cash Cadence

Realty Income is built for this fight. It pays monthly, with a most recent declared dividend of $0.2715 per share and an annualized forward payout of $3.258. Against a current share price of $58.82, that works out to a headline yield of roughly 5.26%, with the next payment landing October 15, 2026.

Johnson & Johnson pays quarterly. Its most recent dividend was $1.34 per share, with an annualized forward payout of $5.36. On a stock trading at $267.80, that is a yield of only 1.97%.

Winner: Realty Income. A retiree pulling cash to cover monthly bills gets roughly 2.7 times the current yield and a payment cadence that matches a mortgage or utility bill (if that 30-day rhythm is the whole appeal, we rounded up seven monthly payers in a free report here).

O price target

Round 2: Dividend Durability

Safety matters more than frequency. This is where the story flips. J&J is a Dividend King with 64 consecutive years of dividend increases, an AAA-rated balance sheet historically, and roughly $21 billion in cash and marketable securities against a full-year free cash flow outlook approaching $21 billion. CFO Joe Wolk was explicit on the Q2 2026 call: “We also remain committed to returning capital directly to shareholders, primarily through our dividend.” The portfolio spans 28 products and platforms, each generating more than $1 billion in annual revenue.

Realty Income’s record is nothing to sneeze at: 115 consecutive quarterly dividend increases and 670+ consecutive monthly dividends since its 1994 NYSE listing. But it carries a P/E of 43, net debt/EBITDA of 7.9x, and derives 65.7% of annualized base rent from non-investment-grade tenants. With the 10-year Treasury yield at 4.97%, its 5.26% payout is competing with a risk-free alternative.

Winner: Johnson & Johnson. A six-decade streak backed by AAA-caliber credit and $21 billion in annual free cash flow beats a REIT with elevated leverage and interest-rate exposure.

JNJ price target

Round 3: Growth and Total Return

JNJ raised full-year 2026 guidance to reported sales of $101.1 billion at the midpoint and adjusted operational EPS of $11.50 to $11.65, with growth engines like DARZALEX up 22.5% and TREMFYA up 68.3%. The stock is up 31.49% year to date and 54.35% over the past year, with a beta of just 0.235.

JNJ earnings explorer

Realty Income guided full-year 2026 AFFO per share to $4.44 to $4.45, roughly 4% growth at the midpoint. The stock is up only 8% YTD and has returned 14.88% over five years against JNJ’s 86.33%.

Winner: Johnson & Johnson. Faster earnings growth, lower volatility, and dramatically better price appreciation.

Verdict

Johnson & Johnson is the better retirement-income holding for any retiree with a horizon longer than a couple of years. Monthly cash flow has genuine budgeting utility, but frequency alone tells you nothing about dividend safety or total return. JNJ’s 64-year streak, AAA-caliber balance sheet, diversified pharma and MedTech engine, and superior total return make it the more reliable compounder of retirement wealth.

Realty Income wins only for one specific profile: a retiree already drawing down the portfolio who needs a high, predictable monthly check today and is comfortable with REIT-specific interest-rate risk. For everyone else planning to fund 15 or 20 years of retirement, JNJ is the stronger long-term holding.

Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.

His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.

When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.

All articles →